Dynavax Technologies Corp. (NASDAQ:DVAX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Several other equities research analysts also recently issued reports on DVAX. S&P Equity Research raised their price objective on shares of Dynavax Technologies Corp. from $11.28 to $16.01 in a research note on Friday, September 2nd. Cowen and Company restated an “outperform” rating and issued a $45.00 price objective on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. RBC Capital Markets restated a “sector perform” rating and issued a $16.00 price objective on shares of Dynavax Technologies Corp. in a research note on Wednesday, September 7th. Finally, William Blair restated a “buy” rating and issued a $45.00 price objective on shares of Dynavax Technologies Corp. in a research note on Tuesday, September 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $20.14.

Analyst Recommendations for Dynavax Technologies Corp. (NASDAQ:DVAX)

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) opened at 4.75 on Monday. Dynavax Technologies Corp. has a 12 month low of $3.20 and a 12 month high of $29.86. The firm has a 50-day moving average price of $8.70 and a 200 day moving average price of $13.04. The firm’s market capitalization is $183.00 million.

Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.15. The company earned $0.20 million during the quarter, compared to analyst estimates of $2.44 million. Dynavax Technologies Corp. had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. The company’s revenue was down 83.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.82) EPS. On average, analysts anticipate that Dynavax Technologies Corp. will post ($3.21) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this report can be accessed at http://www.financial-market-news.com/zacks-investment-research-upgrades-dynavax-technologies-corp-dvax-to-hold-2/1209793/.

Hedge funds and other institutional investors have recently modified their holdings of the company. Emerald Acquisition Ltd. bought a new position in shares of Dynavax Technologies Corp. during the second quarter worth about $472,000. California State Teachers Retirement System boosted its position in shares of Dynavax Technologies Corp. by 5.0% in the second quarter. California State Teachers Retirement System now owns 81,505 shares of the biopharmaceutical company’s stock worth $1,188,000 after buying an additional 3,851 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Dynavax Technologies Corp. by 472.5% in the second quarter. Nordea Investment Management AB now owns 43,513 shares of the biopharmaceutical company’s stock worth $634,000 after buying an additional 35,913 shares during the last quarter. CAM Group Holding A S boosted its position in shares of Dynavax Technologies Corp. by 18.8% in the second quarter. CAM Group Holding A S now owns 189,962 shares of the biopharmaceutical company’s stock worth $2,770,000 after buying an additional 30,000 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its position in shares of Dynavax Technologies Corp. by 13.3% in the second quarter. GW&K Investment Management LLC now owns 160,213 shares of the biopharmaceutical company’s stock worth $2,336,000 after buying an additional 18,794 shares during the last quarter. 82.28% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies Corp.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Get a free copy of the Zacks research report on Dynavax Technologies Corp. (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.